Organovo Holdings, INC

VivoSim Labs, Inc. announced its 2026 Annual Meeting of Stockholders will be held on September 30, 2026, with a record date of August 13, 2026, and outlined deadlines for shareholder nominations and proposals.

VivoSim Labs received a notice from Nasdaq for failing to meet minimum stockholders equity requirements but has a plan to regain compliance, bolstered by recent transactions.

VivoSim Labs announced the pricing of a $4.0 million private placement of common stock and warrants to a single healthcare-focused institutional investor.

VivoSim Labs, Inc. announced the results of its 2025 Annual Meeting, where stockholders elected two Class II directors and approved executive compensation.

VivoSim Labs strengthens its leadership with the appointment of Tony Lialin as Chief Commercial Officer, aiming to scale its AI-enabled 3D human tissue toxicology services.

VivoSim Labs, Inc. has been notified by Nasdaq that it has regained compliance with minimum stock price and stockholders' equity requirements, avoiding delisting.

VivoSim Labs, Inc. reports substantial doubt about its ability to continue as a going concern, despite a strategic pivot to 3D human tissue models for drug testing and the sale of its FXR program.

VivoSim Labs, Inc. reports a reduced net loss but faces substantial doubt about its ability to continue as a going concern, despite a strategic shift to 3D human tissue models and promising liver toxicology platform results.

Organovo Holdings reports Q3 2025 financial results, highlighting ongoing efforts in FXR314 development and 3D tissue modeling, while acknowledging substantial doubt about its ability to continue as a going concern.

Organovo Holdings, Inc., a clinical-stage biotechnology company, reported progress in its development of FXR314 for inflammatory bowel disease and its 3D tissue models, while also facing a Nasdaq minimum bid price deficiency notice.

Organovo Holdings reported its first quarter 2025 results, highlighting a focus on advancing its FXR314 program and developing 3D tissue models for drug discovery.

Organovo Holdings reports a net loss of $3.6 million for the third quarter of 2023, as it shifts focus to clinical drug development and 3D tissue models.

VivoSim Labs, Inc. (VIVS) has transitioned from a clinical-stage biotechnology company to a pharmaceutical and biotechnology services provider focused on 3D human tissue models for drug testing.

VivoSim Labs, Inc. filed an amendment to its annual report to provide detailed information on executive compensation, corporate governance, and related party transactions, including a change in its Chief Financial Officer and auditor, while its auditor noted substantial doubt about the company's ability to continue as a going concern.

VivoSim Labs, Inc. has strategically shifted its business focus to providing 3D human tissue models for drug testing, securing an initial $10 million from Eli Lilly for its former FXR program, while successfully regaining compliance with Nasdaq listing requirements.

Organovo Holdings has filed an amendment to its annual report to include previously omitted information regarding executive compensation, director details, and corporate governance.

Organovo Holdings, a clinical-stage biotech company, released its 10-K filing for the fiscal year ended March 31, 2024, highlighting its focus on advancing FXR314 for inflammatory bowel disease and developing 3D human tissue models for drug discovery.

VivoSim Labs Director Douglas Cohen reported the acquisition of 15,000 restricted stock units, vesting by January 2027.

VivoSim Labs' Executive Chairman, Keith Murphy, acquired 15,000 restricted stock units, increasing his beneficial ownership to 26,053 shares.

VivoSim Labs director Alison Milhous received a grant of 15,000 restricted stock units, which will vest by early 2027.

VivoSim Labs Director David Gobel received a grant of 15,000 restricted stock units, vesting in early 2027 or upon the next annual meeting.

VivoSim Labs Director Adam Stern reported the acquisition of 15,000 restricted stock units, bringing his total beneficial ownership to 19,899 shares.

VivoSim Labs' Chief Scientific Officer, Amar Akhtar Sethi, was granted 53,500 stock options with an exercise price of $2.19, vesting over four years.

Organovo Holdings, Inc. announced its 2023 Annual Meeting of Stockholders to vote on director elections, auditor ratification, executive compensation, an employee stock purchase plan, and a corporate charter amendment.

VivoSim Labs, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 16, 2025, where key proposals include director elections, auditor ratification, and advisory votes on executive compensation.

Organovo Holdings, Inc. announces its 2023 Annual Meeting of Stockholders to be held on October 31, 2023, outlining proposals for director elections, auditor ratification, executive compensation, employee stock purchase plan approval, and certificate of incorporation amendment.

Organovo Holdings is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.

VivoSim Labs, Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 9,411,766 shares of common stock.

VivoSim Labs, Inc. files an S-1/A for a best efforts public offering of up to $4 million in common stock and warrants, aiming to fund operations through 2027 despite significant accumulated losses and auditor's going concern warning.

VivoSim Labs, a biotech services firm, is conducting a best efforts public offering of up to $4 million in common stock and warrants to fund operations, despite an auditor's 'going concern' warning and significant accumulated losses.

Organovo Holdings, Inc. plans to raise capital through a public offering of common stock and warrants to advance its FXR314 clinical program and 3D tissue development efforts.

Organovo Holdings seeks to raise capital through a public offering to fund the clinical development of FXR314 for inflammatory bowel disease and further its 3D tissue technology.

Organovo Holdings seeks to raise up to $10 million through a common stock and pre-funded warrant offering to fund working capital and advance its FXR314 program for inflammatory bowel disease.

Esousa Group Holdings LLC and Michael Wachs have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in VivoSim Labs, Inc.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting their beneficial ownership in Organovo Holdings, Inc. has decreased to 4.99% of the common stock.

Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 9.99% in Organovo Holdings, Inc., totaling 1,700,684 shares.